Conjugates of folic acids with BSA-coated quantum dots for cancer cell targeting and imaging by single-photon and two-photon excitation

被引:0
作者
He Meng
Ji-Yao Chen
Lan Mi
Pei-Nan Wang
Mei-Ying Ge
Yang Yue
Ning Dai
机构
[1] Fudan University,State Key Laboratory of Surface Physics, Department of Physics
[2] Fudan University,Department of Optical Science and Engineering
[3] Chinese Academy Science,National Laboratory for Infrared Physics, Shanghai Institute of Technical Physics
来源
JBIC Journal of Biological Inorganic Chemistry | 2011年 / 16卷
关键词
Quantum dots; Folic acid; Cancer detection; Two-photon excitation;
D O I
暂无
中图分类号
学科分类号
摘要
Bovine serum albumin (BSA)-coated CdTe/ZnS quantum dots (BSA–QDs) were selected to conjugate with folic acid (FA), forming FA–BSA–QDs. This study aims to develop these small FA–BSA–QDs (less than 10 nm) for the diagnosis of cancers in which the FA receptor (FR) is overexpressed. The enhancement of cellular uptake in FR-positive human nasopharyngeal carcinoma cells (KB cells) for FA–BSA–QDs was found by means of confocal fluorescence microscopy under single-photon and two-photon excitation. The uptake enhancement for FA–BSA–QDs was further evaluated by flow-cytometric analysis in 104 KB cells, and was about 3 times higher than for BSA–QDs on average. The uptake enhancement was suppressed when KB cells had been pretreated with excess FA, reflecting that the enhancement was mediated by the association of FR at cell membranes with FA–BSA–QDs. When human embryonic kidney cells (293T) (FR-negative cells) and KB cells, respectively, were incubated with FA–BSA–QDs (1 μM) for 40 min, the FA–BSA–QD uptake by 293T cells was much weaker than that by KB cells, demonstrating that FA–BSA–QDs could undergo preferential binding on FR-positive cancer cells. These characteristics suggest that FA–BSA–QDs are potential candidates for cancer diagnosis.
引用
收藏
页码:117 / 123
页数:6
相关论文
共 185 条
  • [1] Steven DW(1992)undefined Cancer Res 52 6708-6711
  • [2] Arthur GW(1994)undefined Cancer 73 2432-2443
  • [3] Leslie RC(1996)undefined J Nucl Med 37 1003-1008
  • [4] Vincent RZ(2006)undefined Eur Radiol 16 1054-1065
  • [5] Debra SJ(2002)undefined Acad Radiol 9 S316-S319
  • [6] Barton AK(2010)undefined Biomaterials 31 714-729
  • [7] John FR(2003)undefined J Biomed Opt 8 636-641
  • [8] Prabir KC(2004)undefined Adv Drug Delivery Rev 56 1205-1217
  • [9] Manohar R(2006)undefined Expert Rev Mol Diagn 6 879-890
  • [10] Mathias CJ(2006)undefined Biochem Biophys Res Commun 348 781-786